UNSPSC 51393205: Tiamenidine hydrochloride

This classification denotes an alpha-adrenergic agonist with the molecular formula C8H10ClN3S.ClH, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 9SE2T8DW90, chemically known as 2-imidazoline, 2-((2-chloro-4-methyl-3-thienyl)amino)-, monohydrochloride but more generally known as tiamenidine hydrochloride, which bears US NIH Compound Identifier 39973. European Medicines Agency schedules Tiamenidine hydrochloride in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB04853MIG.

UNSPSC 51393205 Tiamenidine hydrochloride is a Commodity code that in practice captures pharmaceutical products and drug-related systems procured by state and local health agencies, though recent solicitations show minimal activity directly aligned with tiamenidine itself. The recent opportunities tagged under this code reflect broader pharmaceutical procurement — naloxone and drug deactivation systems for emergency response and harm reduction — rather than tiamenidine-specific buys. State and local governments soliciting under this code span county health departments and state health and human services commissions pursuing pharmaceuticals, medical systems, and related procurement mechanisms to support public health initiatives.

Seminole County, Florida posted IFB 60459723LAS on June 30, 2026, seeking 1,900 units of naloxone and 800 safe drug deactivation systems annually through July 26, 2023, with quarterly deliveries to the county's community health building and all shipping included in bids. The Texas Health and Human Services Commission issued RFI HHS0017013 on April 3, 2026, to gather vendor capabilities for a Therapeutic Pharmacy Initiative direct-to-manufacturer prescriptions program, seeking information on vendor experience with direct contracting, negotiated net pricing models, and outcomes-based agreements outside traditional pharmacy benefit manager arrangements. Recent activity is sparse and geographically narrow; tiamenidine hydrochloride itself does not appear in either opportunity summary, suggesting the code may be misaligned with actual procurement needs or that tiamenidine is purchased through broader pharmaceutical or chemical contracts under different codes.